Navigation Links
Senexis and O2H (Oxygen Healthcare) Announce Medicinal Chemistry Collaboration
Date:2/14/2008

CAMBRIDGE, England, February 14 /PRNewswire/ -- Executives from Senexis and O2H, both located in Cambridge, UK, announced an agreement under which O2H will provide synthetic and computational chemistry services to the drug discovery programmes at Senexis on an FTE basis.

"We believe our collaboration with O2H leverages the complementary expertise of both organisations and will benefit our search for new therapeutics to treat ageing-related diseases by helping Senexis increase the return on its chemistry research budget" said David Scopes, BSc, MSc, PhD - Chief Scientific Officer at Senexis.

Senexis, a recipient of recent Wellcome Trust funding, is a drug development company, dedicated to the discovery of effective treatments and diagnostics for major ageing-related diseases, such as Alzheimer's dementia, type II diabetes and dialysis related amyloidosis. It is now widely believed that the misfolding and aggregation of amyloid-like proteins underlies the pathologies of these different diseases. Senexis has discovered potent and selective compounds that protect cells and tissues from the toxic forms of amyloid. Senexis is funded by BTG plc and the Wellcome Trust. Further information on Senexis can be found at http://www.senexis.com

O2H has its global HQ in the Science Park, Cambridge, UK, project offices in Boston and Tokyo, and a talented team of scientists in its world class discovery research centre in Ahmedabad, India. "Our scientific team in India with our project offices around the world helps our partners to maximise the value of their drug discovery programmes, from initial planning through to lead generation and lead optimisation thereby delivering enormous advantages to our growing portfolio of global clients," says Sunil Shah, CEO, O2H.

Further information on O2H can be found at http://www.oxygenhealthcare.com.

Please contact info@oxygenhealthcare.com

SENEXIS LIMITED OXYGEN HEALTHCARE LTD

Babraham Research Campus 23 Cambridge Science Park

Babraham, Cambridge, UK Cambridge, UK

CB22 3AT CB4 0EY

High resolution logos can be downloaded from http://www.oxygenhealthcare.com/senexis/logos.zip


'/>"/>
SOURCE Senexis and O2H (Oxygen Healthcare)
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Onyx Pharmaceuticals Announces Fourth Quarter and Full Year 2007 Financial Results Teleconference and Webcast
2. GeoPharma Announces Record Revenues in Third Quarter Results
3. Angiotech announces results for the fourth quarter ended December 31, 2007
4. Cell Therapeutics, Inc. (CTI) Announces Cancellation of Approximately $9.1 Million of Existing Notes due 2008
5. Warner Chilcott Announces Earnings Release Date and Conference Call for Fourth Quarter and Full Year 2007 Financial Results
6. Jazz Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2007 Financial Results
7. NightHawk Radiology Holdings, Inc. Announces Senior Executive Departures
8. VLST Corporation Announces Board and Executive Management Appointments
9. Martek to Announce First Quarter 2008 Results on March 5, 2008
10. Advance Nanotech Announces Shareholder Proxy Vote Results
11. Cellegy Pharmaceuticals Announces Signing of Definitive Merger Agreement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016   Boston ... of novel compounds designed to target cancer stemness ... has been granted Orphan Drug Designation from the ... treatment of gastric cancer, including gastroesophageal junction (GEJ) ... inhibitor designed to inhibit cancer stemness pathways by ...
(Date:6/23/2016)... 23, 2016  The Prostate Cancer Foundation (PCF) is pleased to ... faster cures for prostate cancer. Members of the Class of 2016 were selected ... Read More About the Class of 2016 PCF Young Investigators ... ... ...
(Date:6/23/2016)... NC (PRWEB) , ... June 23, 2016 , ... In ... University Hospital in Denmark detail how a patient who developed lymphedema after being treated ... tissue. The results could change the paradigm for dealing with this debilitating, frequent side ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... exhibiting at the Pennsylvania Convention Center and will showcase its product’s latest features ... will also be presenting a scientific poster on Disrupting Clinical Trials in The ...
Breaking Biology Technology:
(Date:4/28/2016)... GOTHENBURG, Sweden , April 28, 2016 ... 1,491.2 M (139.9), up 966% compared with the first quarter of ... Operating profit totaled SEK 589.1 M (loss: 18.8) and the operating ... SEK 7.12 (loss: 0.32) Cash flow from operations was ... , The 2016 revenue guidance is unchanged, SEK 7,000-8,500 M. ...
(Date:4/15/2016)... , April 15, 2016  A new partnership ... more accurate underwriting decisions in a fraction of ... competitively priced and high-value life insurance policies to ... With Force Diagnostics, rapid testing (A1C, ... data readings (blood pressure, weight, pulse, BMI, and ...
(Date:3/31/2016)... RATON, Florida , March 31, 2016 ... LEGX ) ("LegacyXChange" or the "Company") ... for potential users of its soon to be launched ... video ( https://www.youtube.com/channel/UCyTLBzmZogV1y2D6bDkBX5g ) will also provide ... the use of DNA technology to an industry that ...
Breaking Biology News(10 mins):